Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Gilead Sciences intends to exercise its option to acquire Corus Pharma for $365 million. Gilead invested $25 million in Corus in April, becoming the firm's second largest shareholder and gaining the option to buy the rest of the company. Other investors in Corus, which is developing respiratory and infectious disease products, include several investment banks.
This article has been sent to the following recipient: